Respiratorius AB (publ) (XSAT: RESP)
Health Care · Biotechnology · SE
Skr2.28
-2.15% today · -36.2% 1Y
Respiratorius AB (publ) (XSAT: RESP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.94M.
Over the last twelve months the share price has lost 36.2%, trading between 1.19 and 4.37.
Tweenvest scores Respiratorius AB (publ) across four factors: quality 27/100, value 32/100. Its strongest factor is value.
RESP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.94M
- Revenue (TTM)
- $3.10K
- P/E
- —
- EPS
- -0.91
- Dividend yield
- —
- Beta (5Y)
- 1.68
- 52-week high
- Skr4.37
- 52-week low
- Skr1.19
- Avg volume (3M)
- —
- Shares outstanding
- 7.90M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $439.44 | -0.63% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.13 | -0.43% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $815.00 | -2.23% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $148.64 | -6.42% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.